glp 1 antagonist medications Glucagon-like peptide-1 Mapping the effectiveness and risks

C.AdinolfiL

Zepbounds commercial rise showed that dual agonism could become the next dominant mechanism in obesity care

GIP (Glucose-Dependent Insulinotropic Polypeptide) Enhances insulin secretion and may influence fat metabolism, lipid storage, and energy expenditure

It works by disrupting the FOXO4-p53 interaction inside senescent cells

Research spanning over 40 years demonstrates GHK-Cu affects more than 31% of human genes, with documented benefits including a 70% increase in collagen production, 30-50% faster wound healing, and hair growth comparable to 5% minoxidil

As a preventive cardiologist, I want all patients with heart conditions and their primary care doctors to understand why this development is causing so much excitement and what it might mean for treating and preventing cardiovascular conditions